You spent $40,000 developing a product and $12,000 patenting it. When the books are done right, the $40,000 vanishes into this year's expenses and only the $12,000 shows up as an asset — the exact opposite of what your gut says the "valuable" part was. Get this backwards and you overstate assets, understate expenses, and hand your tax preparer a reconciliation headache. The rules are simpler than they look: creation is expensed, acquisition is capitalized, and legal fees sit on the fault line between the two.
This guide covers how U.S. GAAP treats patent and trademark costs — what hits the income statement immediately, what lands on the balance sheet, how amortization works, where the tax return diverges, and the mistakes small businesses make most often.
The core rule: creation is expensed, acquisition is capitalized
Accounting draws a hard line between building an intangible asset yourself and buying one from someone else:
- Internally developed intangibles are expensed as incurred. Under ASC 350-30-25-3, the costs of internally developing, maintaining, or restoring intangible assets that are not specifically identifiable get recognized as expense when incurred. Research and development costs fall under ASC 730, which requires expensing in the period incurred — even when the work leads to a successful, patentable invention.
- Acquired intangibles are capitalized at cost. When you buy a patent, trademark, or copyright from someone else, the full acquisition cost — purchase price plus directly related costs like legal fees — goes on the balance sheet as an intangible asset.
The logic is conservatism about uncertainty. At the moment you spend R&D dollars, nobody knows whether a marketable asset will result, so accounting refuses to book an asset. A purchase price, by contrast, is arm's-length evidence of value: a willing buyer paid a known amount, so there is something objective to record.
One practical carve-out matters for small businesses: if your total patent filing costs fall below your company's capitalization threshold, expense them even though the rules would otherwise capitalize them. A startup spending $1,800 on a micro-entity filing gains nothing by carrying a tiny amortizing asset for 20 years. Set a written threshold and follow it consistently.
Patents: expense the invention, capitalize the registration
A patent's accounting splits exactly where the lab work ends and the lawyer's work begins.
Expensed: everything that created the invention. Lab salaries, prototype materials, testing, consultant fees, failed experiments — all research and development under ASC 730, expensed in the period incurred. It does not matter that the R&D succeeded and a patent issued. Success does not retroactively convert last year's expenses into an asset.
Capitalized: the direct costs of securing the patent. Attorney fees for drafting and prosecuting the application, USPTO filing fees, and related registration costs are capitalized as a patent intangible asset. These are specifically identifiable costs tied to a granted legal right, not open-ended research.
Purchased patents capitalize fully. If you buy a patent from another company for $50,000 plus $4,000 in legal fees to paper the transfer, the asset goes on the books at $54,000.
Amortization runs over the shorter of legal life or useful life. A U.S. utility patent's legal life is 20 years from filing, but changing technology often makes the economic life shorter. A patent on a phone accessory with a five-year market window amortizes over five years, not twenty. GAAP requires straight-line amortization with no salvage value, and unlike depreciation, amortization typically credits the asset account directly rather than using an accumulated amortization contra account:
- Debit Amortization Expense $1,000; Credit Patents $1,000 — each year until the cost is fully amortized.
Review the useful life periodically. If a competitor's breakthrough cuts your patent's remaining economic life from twelve years to three, the amortization schedule changes going forward — and an impairment test may be due.
Trademarks: capitalized, but (usually) never amortized
Trademarks follow the same expense-versus-capitalize split at birth, then diverge completely afterward.
At birth, the same split applies. The costs of developing a brand internally — logo design, naming consultants, launch marketing — are expensed as incurred. What you capitalize are the direct costs of securing the legal right: attorney fees for the trademark application, USPTO filing fees, and the cost of a purchased trademark including transfer-related legal fees.
After that, most trademarks are never amortized. A federal trademark registration lasts ten years but renews indefinitely for as long as you keep using the mark and filing the maintenance paperwork. Because no foreseeable limit exists on the period the mark will generate cash flows, GAAP classifies it as an indefinite-lived intangible asset under ASC 350-30 — and indefinite-lived assets are not amortized at all. The asset sits on the balance sheet at cost until something impairs it.
Instead of amortization, test for impairment at least annually. Compare the trademark's carrying amount to its fair value; if carrying value exceeds fair value, write it down and recognize an impairment loss. A rebrand, a discontinued product line, or reputational damage can all trigger a write-down between annual tests. Trademark renewal filing fees are generally added to the asset's carrying amount when paid.
The exception that proves the rule: a trademark with a contractually limited life — say, a licensed character mark you may use for exactly three years — is finite-lived and amortizes over that term like a patent. Indefinite life is a conclusion you must support, not a default you get for free.
Defending your IP: success capitalizes, failure expenses
Infringement litigation produces the sharpest expense-versus-capitalize fork in this whole area, and it turns entirely on the outcome:
- Successful defense: capitalize. Legal fees paid to defend a patent or trademark successfully are added to the asset's carrying amount, then amortized over the remaining life (the shorter of remaining legal life and remaining useful life). You spent money that preserved and confirmed a valuable right, so the spending joins the asset.
- Unsuccessful defense: expense — and usually write off the asset. If you lose, the fees hit the income statement immediately. Worse, a lost patent defense often means the underlying asset is worthless, so the remaining unamortized balance gets written off too. Losing a defense case is a double hit to the income statement in a single period.
This asymmetry is worth understanding before you sue or countersue. Budget the legal spend as a contingent asset addition, but understand that an adverse ruling converts both the fees and the carrying value into current-period losses.
The tax return plays by different rules
Everything above is book accounting. The federal tax return follows its own script, and the two scripts disagree most where trademarks are concerned.
Section 197 forces most acquired intangibles into a flat 15-year amortization. When you acquire patents, trademarks, trade names, copyrights, goodwill, customer lists, or non-compete agreements as part of buying a business, the Internal Revenue Code requires straight-line amortization over 15 years (180 months), starting in the month of acquisition — regardless of GAAP classification or actual useful life. A trademark that GAAP never amortizes still amortizes over 15 years on the tax return. A patent with five years of economic life left still amortizes over 15 years for tax.
Self-created intangibles generally stay expensed for tax too. Your R&D deductions and the immediate expensing of brand-development costs carry over — there is nothing to amortize because nothing was capitalized. (Purchased separately outside a business acquisition, a patent generally amortizes over its remaining legal or useful life for tax as well, not the 15-year schedule.)
The gap creates a book-tax difference you must track. When tax amortization exceeds book amortization — the trademark case — taxable income runs lower than book income in the early years, producing a deferred tax liability that reverses later. Corporations reconcile this on Schedule M-1. Even if you are a pass-through owner who never touches a deferred-tax calculation, keep two schedules: one showing book amortization for your financial statements, one showing tax amortization for the return. Commingling them guarantees one of the two is wrong.
Mistakes small businesses make with IP costs
Bundling R&D under "legal" and capitalizing the whole pile. The most expensive mistake runs in the capitalize-too-much direction: engineer time, prototype costs, and patent prosecution fees all land in one "legal / IP" bucket, and the whole bucket gets capitalized. That overstates assets and — worse — defers deductions you could have taken this year. Track prosecution effort separately from development effort from day one.
Capitalizing immaterial amounts. Booking a $900 trademark filing as a permanent balance-sheet asset creates tracking work that exceeds any benefit. Set a capitalization threshold in writing and expense everything below it.
Amortizing an indefinite-lived trademark. Recording annual amortization on a renewable trademark understates both assets and income. If the mark renews indefinitely, the annual event is an impairment review, not an amortization entry.
Skipping the useful-life and impairment reviews. Patent amortization schedules go stale as technology moves; trademark carrying values go stale as brands fade. An annual review of remaining lives and impairment indicators is part of the accounting, not optional diligence.
Forgetting the losing-defense write-off. After an unsuccessful defense, some businesses expense the legal fees but leave the original patent balance amortizing for years. If the patent is dead, the asset is dead — write it off in the same period.
How this looks in your books
A small manufacturer spends $8,500 developing a prototype (expensed as R&D), pays $12,000 in patent attorney and filing fees (capitalized), then amortizes the patent straight-line over its 20-year life ($600 per year). In a plain-text ledger, the sequence looks like this:
2026-03-10 open Assets:Cash:Checking USD
2026-03-10 open Expenses:Research-Development USD
2026-03-10 open Assets:Intangible:Patents USD
2026-03-10 open Expenses:Amortization USD
2026-03-12 * "Prototype materials and lab time"
Expenses:Research-Development 8500.00 USD
Assets:Cash:Checking
2026-06-20 * "Patent attorney drafting and USPTO filing fees"
Assets:Intangible:Patents 12000.00 USD
Assets:Cash:Checking
2026-12-31 * "Annual patent amortization, 12000 over 20 years"
Expenses:Amortization 600.00 USD
Assets:Intangible:PatentsNote the amortization entry credits the asset directly — no accumulated-amortization account, which is the standard presentation for intangibles. A trademark purchase would use the same structure with an Assets:Intangible:Trademarks account, minus the amortization entry: the balance sits untouched until an impairment review says otherwise. If you keep your books this way, the documentation on plain-text accounting shows how these entries flow into balance-sheet and income-statement reports.
Your next useful step
Pull your current-year spending on anything patent- or trademark-related and sort every dollar into three buckets: development costs to expense now, registration and acquisition costs to capitalize, and amortization or impairment entries to book before year-end. Then check that your tax schedule amortizes acquired intangibles over 15 years even where your books do not. That one sorting exercise fixes the R&D bundling mistake, the trademark amortization mistake, and the book-tax commingling mistake in a single pass.
